{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:01:16Z","timestamp":1790049676965,"version":"4.0.1"},"reference-count":19,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Infection caused by\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Mycobacterium avium<\/jats:named-content>\n            is common in AIDS patients who do not receive treatment with highly active antiretroviral therapy (HAART) or who develop resistance to anti-HIV therapy. Mefloquine, a racemic mixture used for malaria prophylaxis and treatment, is bactericidal against\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">M. avium<\/jats:named-content>\n            in mice. MICs of (+)-erythro-, (\u2212)-erythro-, (+)-threo-, and (\u2212)-threo-mefloquine were 32 \u03bcg\/ml, 32 \u03bcg\/ml, 64 \u03bcg\/ml, and 64 \u03bcg\/ml, respectively. The postantibiotic effect for (+)-erythro-mefloquine was 36 h (MIC) and 41 h for a concentration of 4\u00d7 MIC. The mefloquine postantibiotic effect was 25 h (MIC and 4\u00d7 MIC). After baseline infection was established (7 days), the (+)- and (\u2212)-isomers of the diastereomeric threo- and erythro-\u03b1-(2-piperidyl)-2,8-bis(trifluoromethyl)-4-quinolinemethanol were individually used to orally treat C57BL\/6 bg\n            <jats:sup>+<\/jats:sup>\n            \/bg\n            <jats:sup>+<\/jats:sup>\n            beige mice that were infected intravenously with\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">M. avium<\/jats:named-content>\n            . Mice were also treated with commercial mefloquine and diluent as controls. After 4 weeks of treatment, the mice were harvested, and the number of bacteria in spleen and liver was determined. Mice receiving (+)- or (\u2212)-threo-mefloquine or (\u2212)-erythro-mefloquine had numbers of bacterial load in tissues similar to those of untreated control mice at 4 weeks. Commercial mefloquine had a bactericidal effect. However, mice given the (+)-erythro-enantiomer for 4 weeks had a significantly greater reduction of bacterial load than those given mefloquine. Thus, (+)-erythro-mefloquine is the active enantiomer of mefloquine against\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">M. avium<\/jats:named-content>\n            and perhaps other mycobacteria.\n          <\/jats:p>","DOI":"10.1128\/aac.00320-12","type":"journal-article","created":{"date-parts":[[2012,5,22]],"date-time":"2012-05-22T02:55:06Z","timestamp":1337655306000},"page":"4202-4206","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":23,"title":["Identification of (+)-Erythro-Mefloquine as an Active Enantiomer with Greater Efficacy than Mefloquine against Mycobacterium avium Infection in Mice"],"prefix":"10.1128","volume":"56","author":[{"given":"Luiz E.","family":"Bermudez","sequence":"first","affiliation":[{"name":"Kuzell Institute for Arthritis and Infectious Diseases, San Francisco, California, USA"},{"name":"Department of Biomedical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clark B.","family":"Inderlied","sequence":"additional","affiliation":[{"name":"Children's Hospital of Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kolonoski","sequence":"additional","affiliation":[{"name":"Kuzell Institute for Arthritis and Infectious Diseases, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Chee","sequence":"additional","affiliation":[{"name":"Kuzell Institute for Arthritis and Infectious Diseases, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Aralar","sequence":"additional","affiliation":[{"name":"Children's Hospital of Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Petrofsky","sequence":"additional","affiliation":[{"name":"Kuzell Institute for Arthritis and Infectious Diseases, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toufan","family":"Parman","sequence":"additional","affiliation":[{"name":"SRI International, Menlo Park, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol E.","family":"Green","sequence":"additional","affiliation":[{"name":"SRI International, Menlo Park, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita H.","family":"Lewin","sequence":"additional","affiliation":[{"name":"Research Triangle Institute, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Y.","family":"Ellis","sequence":"additional","affiliation":[{"name":"Walter Reed Army Research Institute, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lowell S.","family":"Young","sequence":"additional","affiliation":[{"name":"Kuzell Institute for Arthritis and Infectious Diseases, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-5231(02)00022-9"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.280.5368.1432"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705721"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1997.tb06047.x"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.217-222.2001"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/375352"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.8.1870"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/infdis\/166.4.923","article-title":"Postantibiotic effect of amikacin and rifapentine against Mycobacterium avium complex","volume":"166","author":"Bermudez LE","year":"1992","unstructured":"BermudezLE WuM YoungLS InderliedCB. 1992. Postantibiotic effect of amikacin and rifapentine against Mycobacterium avium complex. J. Infect. Dis. 166:923\u2013926.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1021\/jm00248a015","article-title":"Optical isomers of aryl-2-piperidylmethanol antimalarial agents. Preparation, optical purity, and absolute stereochemistry","volume":"17","author":"Carroll FI","year":"1974","unstructured":"CarrollFI BlackwellJT. 1974. Optical isomers of aryl-2-piperidylmethanol antimalarial agents. Preparation, optical purity, and absolute stereochemistry. J. Med. Chem. 17:210\u2013219.","journal-title":"J. Med. Chem."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI2901"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0272-5231(02)00017-5","article-title":"Nontuberculous mycobacteria in the setting of cystic fibrosis","volume":"23","author":"Ebert DL","year":"2002","unstructured":"EbertDL OlivierKN. 2002. Nontuberculous mycobacteria in the setting of cystic fibrosis. Clin. Chest Med. 23:655\u2013663.","journal-title":"Clin. Chest Med."},{"key":"e_1_3_2_13_2","first-page":"73","article-title":"Falciparum malaria in eastern Thailand: a randomized trial of the efficacy of a single dose of mefloquine","volume":"72","author":"Fontanet AL","year":"1994","unstructured":"FontanetAL. 1994. Falciparum malaria in eastern Thailand: a randomized trial of the efficacy of a single dose of mefloquine. Bull. World Health Organ. 72:73\u201381.","journal-title":"Bull. World Health Organ."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600830613"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s002280050180","article-title":"Comparison between concentrations of racemic mefloquine, its separate enantiomers and the carboxylic acid metabolite in whole blood serum and plasma","volume":"51","author":"Hellgren U","year":"1996","unstructured":"HellgrenU JastrebovaJ JerlingM KrysenB BergqvistY. 1996. Comparison between concentrations of racemic mefloquine, its separate enantiomers and the carboxylic acid metabolite in whole blood serum and plasma. Eur. J. Clin. Pharmacol. 51:171\u2013173.","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.8.1838"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.6.3.266"},{"key":"e_1_3_2_18_2","volume-title":"Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother","author":"Lenaerts AJ","year":"2009","unstructured":"LenaertsAJ. 2009. Mefloquine, moxifloxacin and pyrazinamide is a triple-drug alternative to isoniazid- and rifampin-containing regimens for treatment of tuberculosis in mice, abstr B-1873. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF00193485","article-title":"Whole blood concentrations of mefloquine enantiomers in healthy Thai volunteers","volume":"47","author":"Martin C","year":"1994","unstructured":"MartinC. 1994. Whole blood concentrations of mefloquine enantiomers in healthy Thai volunteers. Eur. J. Clin. Pharmacol. 47:85\u201387.","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200427010-00003"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00320-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00320-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:08:40Z","timestamp":1645481320000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00320-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1128\/AAC.00320-12"],"URL":"https:\/\/doi.org\/10.1128\/aac.00320-12","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"2012-02-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-05-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-07-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}